目的 分析卡瑞利珠单抗致药物不良反应（ADR）发生的临床特点及规律，为临床合理用药提供参考。方法 检索国内外数据库（截至2022年3月1日）关于卡瑞利珠单抗致ADR的文献报道，提取数据并进行分析。结果 卡瑞利珠单抗致ADR个案报道15篇，涉及患者17例，其中男性12例，女性5例，ADR发生年龄多分布在50～79岁（13例，76.47%），且多发生在用药后30 d内（9例，52.94%）。卡瑞利珠单抗致ADR主要以皮肤及其附件损害较多（9例，52.94%），14例经停药和（或）对症治疗后好转或痊愈。结论 卡瑞利珠单抗致ADR涉及多个年龄段患者，累及多个系统/器官，尤其是皮肤及其附件损害较多，需引起高度重视，临床使用时需加强用药监测，综合评估患者利益风险，及早识别药品ADR，及时进行临床处理。

Objective To analyze the clinical characteristics and regularity of adverse drug reaction induced by camrelizumab in order to provide references for rational drug use in clinic. Methods Literature reports of ADR induced by camrelizumab were retrieved from the databases at home and abroad (as of March 1, 2022), and the data were extracted and analyzed. Results There were 15 reported cases of ADR induced by camrelizumab, involving 17 patients, including 12 males and 5 females, mainly aged between 50 and 79 years old (13 cases, 76.47%). Most cases occurred within 30 d after drug administration (9 cases, 52.94%). Skin and accessory damage was the most common primary disease (9 cases, 52.94%). 14 Cases were improved or recovered after drug withdrawal and/or symptomatic treatment. Conclusion ADR caused by carrilizumab involves patients of multiple ages and involves multiple systems/organs, especially skin and its accessories, which requires high attention. Drug monitoring should be strengthened during clinical use, comprehensive assessment of patients' interests and risks, early identification of drug ADR, and timely clinical treatment.

R979.1